UroGen Pharma Q3 2024 GAAP EPS $(0.55) Beats $(0.83) Estimate, Sales $25.20M Beat $24.20M Estimate
UroGen Pharma Q3 2024 GAAP EPS $(0.55) Beats $(0.83) Estimate, Sales $25.20M Beat $24.20M Estimate
UroGen Pharma 2024年第三季度GAAP每股收益为$(0.55)，超过了$(0.83)的预期，销售额为2520万，超过了2420万的预期
UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.83) by 33.73 percent. This is a 19.12 percent increase over losses of $(0.68) per share from the same period last year. The company reported quarterly sales of $25.20 million which beat the analyst consensus estimate of $24.20 million by 4.13 percent. This is a 20.87 percent increase over sales of $20.85 million the same period last year.
UroGen Pharma（纳斯达克股票代码: URGN）报告称，每股亏损0.55美元，超过了分析师共识预期的0.83美元，增幅为33.73%。这比去年同期每股亏损0.68美元增长了19.12%。该公司报告本季度销售额为2520万美元，超过了分析师共识预期的2420万美元，增幅为4.13%。这比去年同期销售额2085万美元增长了20.87%。
资讯热榜
更新时间